Related Experiment Video
Updated: Jul 30, 2026
11:37
Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
Developmental therapeutics for myelodysplastic syndromes
Aung Naing1, Lubomir Sokol, Alan F List
1H. Lee Moffitt Cancer Center & Research Institute, University of South Florida College of Medicine, Tampa, FL, USA.
Journal of the National Comprehensive Cancer Network : JNCCN
|January 13, 2006
Summary
Myelodysplastic syndromes (MDS) management now includes targeted therapies, moving beyond supportive care. Novel treatments, like lenalidomide for specific MDS types, show promising results for patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myelodysplastic syndromes (MDS) management has shifted towards risk-guided active treatments.
- Understanding MDS molecular pathogenesis has spurred the development of novel therapeutics.
- Lenalidomide demonstrates significant efficacy in MDS with chromosome 5q31 deletion.
Purpose of the Study:
- To summarize preliminary results of novel therapeutics for myelodysplastic syndromes.
- To highlight advancements in targeted therapy for MDS.
Main Methods:
- Review of preliminary clinical data for novel MDS therapeutics.
- Focus on agents targeting specific molecular pathways or genetic abnormalities.
Main Results:
- Lenalidomide shows remarkable effectiveness in MDS patients with 5q31 deletion.
- Selected novel therapeutics are in various stages of clinical testing.
Conclusions:
- Novel targeted therapeutics offer potential for improved outcomes in MDS patients.
- The evolving treatment landscape for MDS includes promising new therapeutic options.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.